These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6988911)

  • 61. Tamoxifen and aminoglutethimide in advanced breast cancer.
    Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
    Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
    Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A
    Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
    Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
    De Lena M; Tommasi S; Schittulli F; Lorusso V; Paradiso A
    Tumori; 1990 Apr; 76(2):190-5. PubMed ID: 2139523
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time.
    Noguchi S; Miyauchi K; Nishizawa Y; Koyama H
    Cancer; 1988 Apr; 61(7):1345-9. PubMed ID: 2964264
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of tamoxifen, medroxyprogesterone acetate, and their combination on human endometrial estrogen and progestin receptor concentrations, 17 beta-hydroxysteroid dehydrogenase activity, and serum hormone concentrations.
    Kokko E; Jänne O; Kauppila A; Vihko R
    Am J Obstet Gynecol; 1982 Jun; 143(4):382-8. PubMed ID: 6211985
    [No Abstract]   [Full Text] [Related]  

  • 68. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
    Ingle JN; Mailliard JA; Schaid DJ; Krook JE; Gesme DH; Windschitl HE; Pfeifle DM; Etzell PS; Gerstner JG; Long HJ
    Cancer; 1991 Jul; 68(1):34-9. PubMed ID: 2049750
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thermal gradient and response to estrogens or antiestrogens in advanced breast cancer.
    Di Pietro S; Rovini D; Luini A; Muscolino G; Viganotti G
    Tumori; 1980 Aug; 66(4):459-65. PubMed ID: 7414710
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
    Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
    Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
    Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells.
    Sica G; Lama G; Iacopino F; Angelucći C; Della Cuna GR; Marchetti P
    Anticancer Res; 1991; 11(6):2099-102. PubMed ID: 1776846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Long HJ; Gerstner JG; Windschitl HE
    J Clin Oncol; 1988 May; 6(5):825-31. PubMed ID: 3284975
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
    Harvell DM; Richer JK; Singh M; Spoelstra N; Finlayson C; Borges VF; Elias AD; Horwitz KB
    Breast Cancer Res Treat; 2008 Dec; 112(3):489-501. PubMed ID: 18338247
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Steroid receptor expression in endometria from women treated with tamoxifen.
    Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
    Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.